KindredBio Announces Launch of Initial Public Offering

SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to […]

KindredBio Announces Appointment of Stephen Sundlof, Former Director of FDA’s CVM, as Senior Vice President of Regulatory Affairs

SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.

KindredBio Announces Initiation of Pivotal Clinical Study for CereKin™

CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol […]

KindredBio Appoints Kevin Schultz, Former CSO of Merial, as CSO

Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the KindredBio team. SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Kevin Schultz, DVM, PhD, former Chief Scientific Officer and Head of R&D for Merial, as Chief Scientific Officer and Head of […]

KindredBio Announces Protocol Concurrences from the FDA on Pivotal Studies

FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies. SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) […]